ClinicalTrials.gg
RecruitingNCT05772208Updated Mar 16, 2023

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

A Phase 3 interventional study of Camrelizumab and Nimotuzumab in Nasopharyngeal Carcinoma, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Jan 2022, registered Mar 2023).
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing camrelizumab in Nasopharyngeal Carcinoma — 9 open to participants now, 11 under way, 2 of them phase 3. camrelizumab · Nasopharyngeal Carcinoma.

Planned enrollment
Largest of 17
459 · median 58
Started
2022
with 5 others
Phase 3
3 of 17
2 open now
Primary completion
2025-01
later than 4 of 10 live
Registered
16th of 17
by date
Lead sponsor
2 of 17
Fudan University

Among the 17 studies testing camrelizumab in Nasopharyngeal Carcinoma, this one has the largest planned enrollment, is one of 6 that started in 2022, is one of 3 in phase 3, reaches primary completion later than 4 of the 10 other live ones, and was the 16th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

9 of the 17 studies testing camrelizumab in Nasopharyngeal Carcinoma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing camrelizumab in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

The goal of this multicenter randomized non-inferior study is to compare the additon of camrelizumab or nimotuzumab to neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients whose EBV DNA remained detectable after one cycle neoadjuvant chemotherapy using GP regimen. The main question it aims to answer is: whether the addition of carrilizumab or nituzumab improve the treatment outcomes in the relatively poor prognostic patients identified by the response of EBV DNA. Participants will be randomized to the combination of carrilizumab and standard treatment , the combination of nituzumab and standard treatment or the standard treatment alone if their EBV DNA didn't decrease to undetectable level post first cycle of neoadjuvant chemotherapy.

03

Conditions studied

  • Nasopharyngeal Carcinoma

Keywords

  • EBV DNA
  • camrelizumab
  • nimotuzumab
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with newly confirmed non-keratinizing nasopharyngeal carcinoma, type of WHO II or III, EGFR+.
  2. Age 18-70 years.
  3. Clinical stage III-IVa (based on the 8th American Joint Committee on Cancer[AJCC] edition).
  4. Patients with detectable pre-treatment plasma EBV DNA which remained detectable after one cycle .
  5. (Eastern Cooperative Oncology Group) score: 0-1
  6. (HGB) ≥90 g/L, white blood cell (WBC) ≥4×109 /L, (PLT) ≥100×109 /L.
  7. Liver function: (ALT), Aspartate aminotransferase(AST)\< 1.5 times the value (ULN), total \<1.0×ULN.
  8. Renal function: serum creatinine \<1×ULN.
  9. Patients must sign and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.

Exclusion criteria

Exclusion Criteria:

  1. confirmed keratinizing squamous cell carcinoma (WHO I)
  2. Suffered from other malignant tumors (except the cure of basal cell carcinoma or uterine cervical carcinoma in situ) previously.
  3. Receiving radiotherapy or chemotherapy or targeted therapy previously
  4. Women of who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
  5. Patients with significantly lower heart, liver, lung, kidney and bone marrow function.
  6. Severe, uncontrolled medical conditions and infections.
  7. At the same time using other test drugs or in other clinical trials.
  8. Refusal or inability to sign to participate in the trial.
  9. Emotional disturbance or mental
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
459 participants (estimated)

Study arms

  • Experimental
    the combination of camrelizumab and standard treatment

    camrelizumab 200mg q3w 2 cycle combinted with the second and third cycle neoajuvant chemotherapy and camrelizumab 200mg q3w 8 cycle starting one month after concurrent chemo-radiotherapy.

    Drug: Camrelizumab · Drug: neoadjuvant chemotherapy and CCRT

  • Experimental
    the combination of nimotuzumab and standard treatment

    nimotuzumab 200mg qw combined with the second and third cycle neoajuvant chemotherapy and nimotuzumab 200mg qw used during chemo-radiotherapy.

    Drug: Nimotuzumab · Drug: neoadjuvant chemotherapy and CCRT

  • Active comparator
    standard treatment

    the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1,8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.

    Drug: neoadjuvant chemotherapy and CCRT

Interventions

  • camrelizumab 200mg q3w

  • nimotuzumab 200mg qw

  • Drugneoadjuvant chemotherapy and CCRT

    the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1,8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Defined from date of randomization to date of first documentation of progression or death due to any cause

    Time frame: 3 years

Secondary outcomes

  1. Overall survival

    Defined from date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up.

    Time frame: 3 years

  2. Toxicities

    Analysis of acute and late adverse events (AEs) are evaluated. Numbers of patients of treatment-related adverse events(acute toxicity) as assessed by CTCAE v5.0.Numbers of patients of late radiation toxicities were assessed using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jan 2025, 36 months after the start.

Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 16, 2023
StartActual
Jan 1, 2022
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2028
Last update
Mar 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05772208
Lead sponsor
Fudan University
Responsible party
Chaosu Hu (MD and PhD, Fudan University) — Principal investigator
First posted
Mar 16, 2023
Start date
Jan 1, 2022
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Mar 16, 2023

Study contacts

Chengrun Du
Contact
duchengrun@qq.com
+86-15001733593

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Nimotuzumab

Start the discussion